An open label, 2-period, non-inferiority controlled, prospective study comparing the efficacy of generic Sofosbuvir and branded Daclatasvir with Sofosbuvir and Ledipasvir in patients with genotype 4 Hepatitis C Virus
Latest Information Update: 13 Jul 2020
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ledipasvir
- Indications Hepatitis C
- Focus Therapeutic Use
- 13 Jul 2020 New trial record
- 03 Jun 2020 Primary endpoint, Proportion of patients achieving SVR12, has been met as per results presented at the 2020 American Transplant Congress
- 03 Jun 2020 Results presented at the 2020 American Transplant Congress